Rybelsus Alternatives & Comparison
How Rybelsus (semaglutide) compares to Ozempic, Mounjaro, Trulicity — mechanism, trial weight-loss results, and cost — plus where to compare vetted providers.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Rybelsus Alternatives Compared
Same molecule, delivered by injection, which usually gets more out of a comparable dose
Ozempic activates GLP-1 receptors to stimulate glucose-dependent insulin secretion, suppress glucagon, and reduce blood sugar levels.
Identical drug, two delivery routes, and the route is the whole difference. Ozempic is injected weekly; Rybelsus is a daily tablet requiring a strict fast before and after, because the SNAC absorption enhancer only works on an empty stomach. On outcomes, SUSTAIN-6 showed superiority for MACE (HR 0.74) while PIONEER 6 showed non-inferiority (HR 0.79). Retail is around $1,029 and $998. Choose on whether a daily fasting routine or a weekly needle fits your life better.
Full Ozempic vs Rybelsus comparison →Injected, and a dual GIP/GLP-1 agonist. Glycemic and weight effect generally run higher
Mounjaro's tirzepatide activates both GIP and GLP-1 receptors — making it a "dual agonist" or "twincretin." For diabetes, this dual action powerfully lowers blood sugar by increasing insulin secretion and reducing glucagon.
Two diabetes drugs, neither approved for weight management, compared mostly by people who want the weight effect anyway. SURPASS-2 reported −11.2 kg at 40 weeks for Mounjaro; PIONEER 1 reported −4.4 kg at 26 weeks for Rybelsus. Different trials and different durations. Retail sits near $1,029 and $1,069, with Lilly's card requiring commercial insurance. The dosing burden is the honest differentiator: a daily fast, or a weekly injection.
Full Mounjaro vs Rybelsus comparison →A weekly injection instead, with years of real-world safety data behind it
Dulaglutide is a long-acting GLP-1 receptor agonist engineered by fusing two modified GLP-1 peptide chains to a human IgG4 Fc fragment, which extends the half-life to about five days and allows once-weekly dosing.
Both are diabetes drugs, neither is approved for weight management, and the weight figures — −4.4 kg on Rybelsus at 26 weeks, −2 to −3 kg on Trulicity — come from diabetes programs rather than obesity trials. Rybelsus demands the fasting window that oral semaglutide absorption requires; Trulicity is one weekly injection with no food rules. Retail is near $1,029 and $987. For most people this decision is made by the formulary, not by these numbers.
Full Trulicity vs Rybelsus comparison →Compare compounded Semaglutide providers
Compounded semaglutide runs a median of $190/month across 481 vetted-provider price points (range $65–$1,585). Featured partners below, ranked by our partner-economics ordering.
Compare compounded Tirzepatide providers
Compounded tirzepatide runs a median of $258/month across 435 vetted-provider price points (range $83–$1,400). Featured partners below, ranked by our partner-economics ordering.
Compare every Rybelsus provider
See current pricing, verification status, form, and states served across every vetted provider in one place.